Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Purpose: Immune-based therapy for metastatic breast cancer has had limited success,
particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T …
particularly in molecular subtypes with low somatic mutations rates. Strategies to augment T …
Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and αPD-1 enable sustained antitumor responses against established HER2 …
EJ Crosby, CR Acharya, AF Haddad, CA Rabiola… - Clinical Cancer …, 2020 - AACR
Purpose: Despite promising advances in breast cancer immunotherapy, augmenting T-cell
infiltration has remained a significant challenge. Although neither individual vaccines nor …
infiltration has remained a significant challenge. Although neither individual vaccines nor …
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
H Norell, I Poschke, J Charo, WZ Wei, C Erskine… - Journal of translational …, 2010 - Springer
Abstract Background Adjuvant trastuzumab (Herceptin) treatment of breast cancer patients
significantly improves their clinical outcome. Vaccination is an attractive alternative …
significantly improves their clinical outcome. Vaccination is an attractive alternative …
A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer
ML Disis, Y Dang, AL Coveler, JS Childs… - Clinical Cancer …, 2023 - AACR
Purpose: High levels of type IT cells are needed for tumor eradication. We evaluated
whether the HER2-specific vaccine–primed T cells are readily expanded ex vivo to achieve …
whether the HER2-specific vaccine–primed T cells are readily expanded ex vivo to achieve …
A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
G Chen, R Gupta, S Petrik, M Laiko… - Cancer immunology …, 2014 - AACR
Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccines are
bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide …
bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide …
Tailoring DNA vaccines: designing strategies against HER2-positive cancers
C Marchini, C Kalogris, C Garulli, L Pietrella… - Frontiers in …, 2013 - frontiersin.org
The crucial role of HER2 in epithelial transformation and its selective overexpression on
cancer tissues makes it an ideal target for cancer immunotherapies such as passive …
cancer tissues makes it an ideal target for cancer immunotherapies such as passive …
Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
B Wang, N Zaidi, LZ He, L Zhang, JMY Kuroiwa… - Breast cancer …, 2012 - Springer
Introduction Given their relative simplicity of manufacture and ability to be injected
repeatedly, vaccines in a protein format are attractive for breast and other cancers. However …
repeatedly, vaccines in a protein format are attractive for breast and other cancers. However …
HER2-directed therapy for metastatic breast cancer
D Jelovac, LA Emens - Oncology, 2013 - search.proquest.com
Therapeutic cancer vaccines designed to induce immune responses specific for HER2 are
under active investigation for both early-stage and advanced HER2-positive breast …
under active investigation for both early-stage and advanced HER2-positive breast …
Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells
XR Ren, J Wei, G Lei, J Wang, J Lu, W Xia… - Breast Cancer …, 2012 - Springer
Introduction Sustained HER2 signaling at the cell surface is an oncogenic mechanism in a
significant proportion of breast cancers. While clinically effective therapies targeting HER2 …
significant proportion of breast cancers. While clinically effective therapies targeting HER2 …
Sequential anti-PD1 therapy following dendritic cell vaccination improves survival in a HER2 mammary carcinoma model and identifies a critical role for CD4 T cells in …
KN Kodumudi, G Ramamoorthi, C Snyder… - Frontiers in …, 2019 - frontiersin.org
Patients with metastatic HER2 breast cancer (MBC) often become resistant to HER 2
targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 …
targeted therapy and have recurrence of disease. The Panacea trial suggested that HER2 …